Hormonal Receptor Positivity and Clinical Multifocality Are Independent Predisposing Factors for Positive Margin Events in Breast-Conserving Surgery after Neoadjuvant Chemotherapy

키워드

참고문헌 (30)

1. Fisher B, "Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer", N Engl J Med, 347, pp.1233~1241 (2002)
2. Fisher B, "Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18", J Clin Oncol, 15, pp.2483~2493 (1997)
3. Rastogi P, "Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27", J Clin Oncol, 26, pp.778~785 (2008)
4. Rouzier R, "Primary chemotherapy for operable breast cancer:incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery", J Clin Oncol, 19, pp.3828~3835 (2001)
5. Smith IE, "Preoperative", neoadjuvant medical therapy for early breast cancer, 2001, pp.2, 561~570
6. Chen K, "Cavity margin status is an independent risk factor for local-regional recurrence in breast cancer patients treated with neoadjuvant chemotherapy before breast-conserving surgery", Am Surg, 77, pp.1700~1706 (2011)
7. Houssami N, "The association of surgical margins and local recurrence in women with earlystage invasive breast cancer treated with breast-conserving therapy:a meta-analysis", Ann Surg Oncol, 21, pp.717~730 (2014)
8. Harness JK, "Margins: a status report from the Annual Meeting of the American Society of Breast Surgeons", Ann Surg Oncol, 21, pp.3192~3197 (2014)
9. Veronesi U, "Conservation surgery after primary chemotherapy in large carcinomas of the breast", Ann Surg, 222, pp.612~618 (1995)
10. Wang S, "Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors", World J Surg Oncol, 11, pp.166~ (2013)
11. Yoshida T, "Ipsilateral breast tumor relapse after breast conserving surgery in women with breast cancer", Breast, 18, pp.238~243 (2009)
12. Leong C, "Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma", Cancer, 100, pp.1823~1832 (2004)
13. Edge SB, "AJCC Cancer Staging Manual" (2010), Springer
14. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
15. Valejo FA, "Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy", Rev Bras Ginecol Obstet, 35, pp.221~225 (2013)
16. Gianni L, "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial", Lancet Oncol, 13, pp.25~32 (2012)
17. Baselga J, "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial", Lancet, 379, pp.633~640 (2012)
18. Ismael G, "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial", Lancet Oncol, 13, pp.869~878 (2012)
19. Katsumasa Kuroi, "Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG", Breast Cancer, 22(5), pp.486~495 (2015), Springer Nature[DOI]
20. Ishitobi M, "Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index", Cancer, 118, pp.4385~4393 (2012)
21. Mittendorf EA, "Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy", Ann Surg, 257, pp.173~179 (2013)
22. Fisher ER, "Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma", Cancer, 86, pp.429~438 (1999)
23. Luini A, "The surgical margin status after breast-conserving surgery: discussion of an open issue", Breast Cancer Res Treat, 113, pp.397~402 (2009)
24. McCahill LE, "Variability in reexcision following breast conservation surgery", JAMA, 307, pp.467~475 (2012)
25. Margenthaler JA, "Margin index: a new method for prediction of residual disease after breast-conserving surgery", Ann Surg Oncol, 17, pp.2696~2701 (2010)
26. Berg WA, "Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer", Radiology, 233, pp.830~849 (2004)
27. Loo CE, "Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype", J Clin Oncol, 29, pp.660~666 (2011)
28. McGuire KP, "MRI staging after neoadjuvant chemotherapy for breast cancer:does tumor biology affect accuracy?", Ann Surg Oncol, 18, pp.3149~3154 (2011)
29. Huang EH, "Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy", J Clin Oncol, 22, pp.4691~4699 (2004)
30. Bartelink H, "Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial", J Clin Oncol, 25, pp.3259~3265 (2007)

관련 논문AI추천